Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
The Sri Sathya Sai Sanjeevani Super Speciality Hospital in Batticaloa will begin its operations by conducting free paediatric cardiac care surgeries and interventions in the next few days
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Company raises the annual revenue guidance from mid-teens to high teens
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Subscribe To Our Newsletter & Stay Updated
